Clinical Trial Detail

NCT ID NCT02034110
Title Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors GlaxoSmithKline
Indications

thyroid gland cancer

gastrointestinal stromal tumor

biliary tract cancer

germ cell cancer

multiple myeloma

malignant glioma

hairy cell leukemia

small intestine adenocarcinoma

Therapies

Dabrafenib + Trametinib

Age Groups: adult

Additional content available in CKB BOOST